Figure 1.

Best overall percentage change from baseline target lesion measurement by RECIST guidelines.

Note: Three patients had progressive disease as a result of the development of new lesions, rather than growth of the target lesions by 20%. Three additional patients (noted by *) also had progressive disease as a result of the development of new lesions; growth of previously noted lesions in these patients was difficult to quantify.